Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Amprenavir/ritonavir · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| Amprenavir/ritonavir | DRUG | - |
| Saquinavir/ritonavir | DRUG | - |
| Efavirenz | DRUG | - |
Inclusion: * Subject must remain on current antiretroviral therapy during screening until a new regimen is initiated. * Subject demonstrates reduced susceptibility to lopinavir. * Subject's two most recent viral loads obtained after at least 16 weeks of lopinavir/ritonavir therapy, and while still ...
Top 20 of 28 competitors
Amprenavir/ritonavir is an investigational small molecule combination being studied for the treatment of HIV infections. It is in Phase 2 clinical development and has not been approved by the FDA. The drug is being evaluated in HIV-infected patients who have experienced failure with prior protease inhibitor-based therapy.
Amprenavir/ritonavir is being developed by Abbott Laboratories, which trades under the ticker ABT. The company is conducting clinical trials to evaluate the combination in patients with HIV infections who have failed prior protease inhibitor-based regimens.
Amprenavir/ritonavir is in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. Two Phase 2 trials have been completed, with a total enrollment of 40 patients, both studying the drug in HIV-infected subjects.
Amprenavir/ritonavir has been studied in two completed Phase 2 trials: NCT00038519 and NCT00038532. Both trials enrolled HIV-infected adults who had failed prior protease inhibitor-based therapy, with enrollment of 16 and 24 patients respectively. The trials were conducted across multiple countries including the United States, Argentina, Brazil, and several European nations.
Amprenavir/ritonavir is a combination of two protease inhibitors used to treat HIV infections. The combination is designed to enhance the activity of amprenavir by using ritonavir to boost its levels in the body, potentially improving antiviral efficacy in patients who have failed prior protease inhibitor therapy.